Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H16O6P2.2Na.2H |
Molecular Weight | 330.1627 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[Na+].[Na+].[O-]P([O-])(=O)C(CC1CCCCCC1)P([O-])([O-])=O
InChI
InChIKey=RLIRIVMEKVNVQX-UHFFFAOYSA-L
InChI=1S/C9H20O6P2.2Na/c10-16(11,12)9(17(13,14)15)7-8-5-3-1-2-4-6-8;;/h8-9H,1-7H2,(H2,10,11,12)(H2,13,14,15);;/q;2*+1/p-2
Molecular Formula | C9H18O6P2 |
Molecular Weight | 284.1831 |
Charge | -2 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Incadronate (Disodium Cycloheptylaminomethylene diphosphate) is used to treat malignancy-associated hypercalcemia (MAH) in Japan. Experiments on rodents have revealed that this drug could be an effective agent for the treatment of various arthritic conditions, including human rheumatoid arthritis. In addition was shown, that incadronate induced growth inhibition and apoptotic death of pancreatic cancer cells. Incadronate also inhibited migration presumably by preventing the activation of Rho by lysophosphatidic acid. Thus, this drug can be of value in regimens for the treatment of pancreatic cancer.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Hydronium (cycloheptylammonio)methylene-1,1-bisphosphonate (hydronium incadronate). | 2003 Feb |
|
Incadronate disodium inhibits joint destruction and periarticular bone loss only in the early phase of rat adjuvant-induced arthritis. | 2005 |
|
The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis. | 2006 Jun |
|
Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells. | 2007 Mar-Apr |
|
Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study. | 2007 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24683210
Korean patients with malignancy-associated hypercalcemia (MAH) were given a single 10-mg IV infusion of incadronate over 2 to 4 hours in 500 to 1000 mL of normal saline
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:21:16 GMT 2025
by
admin
on
Mon Mar 31 21:21:16 GMT 2025
|
Record UNII |
7L16W0096A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000078559
Created by
admin on Mon Mar 31 21:21:16 GMT 2025 , Edited by admin on Mon Mar 31 21:21:16 GMT 2025
|
PRIMARY | |||
|
SUB16419MIG
Created by
admin on Mon Mar 31 21:21:16 GMT 2025 , Edited by admin on Mon Mar 31 21:21:16 GMT 2025
|
PRIMARY | |||
|
119188
Created by
admin on Mon Mar 31 21:21:16 GMT 2025 , Edited by admin on Mon Mar 31 21:21:16 GMT 2025
|
PRIMARY | |||
|
7L16W0096A
Created by
admin on Mon Mar 31 21:21:16 GMT 2025 , Edited by admin on Mon Mar 31 21:21:16 GMT 2025
|
PRIMARY | |||
|
DB06255
Created by
admin on Mon Mar 31 21:21:16 GMT 2025 , Edited by admin on Mon Mar 31 21:21:16 GMT 2025
|
PRIMARY | |||
|
138330-18-4
Created by
admin on Mon Mar 31 21:21:16 GMT 2025 , Edited by admin on Mon Mar 31 21:21:16 GMT 2025
|
PRIMARY | |||
|
m6239
Created by
admin on Mon Mar 31 21:21:16 GMT 2025 , Edited by admin on Mon Mar 31 21:21:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
C071542
Created by
admin on Mon Mar 31 21:21:16 GMT 2025 , Edited by admin on Mon Mar 31 21:21:16 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
SOLVATE->ANHYDROUS |
|